Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study☆. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426014638?dgcid=rss_sd_all
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study☆. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426014638?dgcid=rss_sd_all
“Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study☆.” Annals of Oncology.
@article{article35805,
title = {Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study☆},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426014638?dgcid=rss_sd_all}
}